Search results
How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
Investor's Business Daily· 6 days agoThe stock has a lower, but still promising, Relative Strength Rating of 83, putting it in the top...
Earnings call: Ironwood Pharmaceuticals reports robust Q1 growth By Investing.com
Investing.com· 5 days agoIronwood Pharmaceuticals, Inc. (NASDAQ: IRWD) provided an update on its financial and operational...
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
Zacks via Yahoo Finance· 5 days agoIronwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss...
Euronext Paris Growth Leaders With High Insider Stakes May 2024
Simply Wall St. via Yahoo Finance· 3 days agoAmid a backdrop of rising optimism in European markets, with France's CAC 40 Index recently climbing...
Sutro Biopharma shares hold on luvelta prospects By Investing.com
Investing.com· 2 days agoThe biopharmaceutical firm has completed enrollment for...targeted ADC, for the treatment of...
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
Zacks via Yahoo Finance· 6 days agoTEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for...
Is Eli Lilly Stock A Better Pick Over Amgen?
Forbes· 3 days agoAlso, Eli Lilly has seen a better revenue growth and is more profitable. There is more to the comparison, and in the sections below, we discuss why we...
Damien Conover and Rebecca Springer: ‘We Are in a Healthcare Consumerization Moment Right Now’
Morningstar· 1 day agoDamien is director of healthcare research and director of equity strategy for Morningstar Research...
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
Zacks· 6 days agoThe top line decreased almost 28% year over year due to a $30.0 million gross-to-net change in estimate for the sole marketed drug, Linzess (linaclotide), recorded to collaborative arrangements ...
Robert Bruce's Strategic Moves in Q1 2024: Spotlight on Xcel Ene
Guru Focus· 2 days agoInsights into the Investment Shifts of Bruce & Co Robert Bruce (Trades, Portfolio), the seasoned investor behind Bruce & Co, has made notable adjustments to hi